Detail

Study ID: CTSU S1609

Title:

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Description:
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Preston Steen, MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
RARE (Rare Tumors), Lung, Non-Small Cell Lung Cancer, Other, RST (Soft Tissue Sarcoma), Skin, Soft Tissue, Vulvar
Stage:
Phase II
Status:
Active - Open to Accrual